Zacks Investment Research
25 Sept 2026, 23:15 UTC · 1h ago
Verdict
Headline leans bullish. We score PACB −0.40 across three claims.
Score contradicts the headline.
Leans bullish
From its wording — no explicit rating
−0.40moderately bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Pacific Biosciences is forecasted to report an EPS of -$0.13 for the upcoming quarter, an 8.33% decline from the prior year.
Priced inZacks Consensus Estimate
So whatA miss against this already lowered EPS floor would likely trigger a further downward revision of the full-year -$0.43 estimate.
More negative than 77% of claims this week
The Zacks Consensus Estimate projects net sales of $37.86 million for the upcoming quarter, down 1.51% year-over-year.
Continue reading
5 related stories
More negative than 71% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inZacks Consensus Estimate
So whatThis quarterly revenue target represents roughly 24% of the $156.1 million full-year projection.
More negative than 70% of claims this week
Full-year Zacks Consensus Estimates call for earnings of -$0.43 per share and revenue of $156.1 million.
Priced inZacks Consensus Estimate
So whatThe revenue forecast implies a -2.44% year-over-year contraction for FY2026.
More negative than 64% of claims this week
Which stocks this story touches
More negative than 71% of ticker scores this week
The company has a Zacks Rank of #4 (Sell) and forecasted declines in both EPS and revenue.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
1h ago
—
PACB hasn't traded since this ran. Last close $1.62 (Sep 25); the reaction starts at the next open.
PACB chart →
